Former director at Carl Zeiss Meditec AG
- Sustainability of Zeiss’ competitive positioning in the IOL (intraocular lens) space, highlighting nuances across materials and product types
- Zeiss' (ETR: AFX) ability to expand EBIT margins, plus pricing outlook and likely growth expectations
- Portfolio analysis, including competitiveness of Quatera 700, highlighting potential US launch and FDA approval
- Outlook for Zeiss' US market revenue growth in ophthalmic surgery
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.